Metrics as of 10/15/2026, 10:21 AM (Berlin time), refresh in progress.
BioVie Stock
BioVie Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Cuong Viet Do
- Employees
- 13
- Market cap
- $10 M
- IPO
- 18/09/2020
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for…
BioVie stock: price history
1D
-3.3%
1W
-17.1%
1M
-43.4%
6M
-17.7%
YTD
+0.0%
1Y
-42.0%
2Y
-89.8%
5Y
-99.8%
10Y
-100.0%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~47% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about BioVie
Analyst assessment of BioVie
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 30/11/2023
BioVie stock metrics
P/E
-0.36
P/B
0.85
EV/EBITDA
-0.06
RETURN ON EQUITY
-55.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.1%
FLOAT SHARES
7,477,922
AVG. DAILY VOLUME (30D)
311,465
Insider transactions (SEC)
DO CUONG V
KIM JOANNE WENDY
Chappell Amy Suzon
Palumbo Joseph M
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about BioVie stock
What does BioVie do?
BioVie Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Cuong Viet Do, the company employs around 13 people.
The IPO was on 18/09/2020; the stock trades on NASDAQ under the ticker BIVI.
What do analysts say about BioVie stock?
5 analysts rate the stock, the consensus is Buy (as of 30/11/2023).
This is an external assessment, not a statement by Market Jury.
When does BioVie report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -47% stronger than usual.
Does BioVie pay a dividend?
No, BioVie currently does not pay a dividend.
Which stocks are comparable to BioVie?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BioVie stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioVie against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.